S
Seaport Therapeutics
Developing new neuropsychiatric medicines, specifically antidepressants and anxiolytics
About Seaport Therapeutics
Seaport is a biotechnology company focused on developing novel antidepressants and anxiolytics. The company operates in the neuropsychiatric disorder treatment market, targeting patients who suffer from conditions such as depression and anxiety. Seaport's unique approach involves creating drugs that are orally bioavailable, avoiding first-pass metabolism, and minimizing hepatotoxicity and other side effects. The business model is centered around advancing these therapeutic candidates through clinical trials, gaining regulatory approval, and eventually bringing them to market. Revenue is generated through the commercialization of these drugs, either directly or through partnerships and licensing agreements with larger pharmaceutical companies. Seaport's leadership team includes experienced professionals with a strong track record in the biotech industry, enhancing the company's credibility and operational efficiency. Keywords: antidepressants, anxiolytics, neuropsychiatric disorders, bioavailability, hepatotoxicity, clinical trials, regulatory approval, biotechnology, drug development, partnerships.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2024
- Headquarters
- Boston, United States
- Employees
- 73
- Open positions
- 4
- Dealroom signal
- 92.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Rumoured $1B, Biotech and Pharma, Psychedelic Drugs, Woman Founder, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | Apr 2026 | $255M | $955M | Undisclosed | ↗ |
| GRANTOther financing | Mar 2026 | $0 | — | Advanced Research Projects Agency for Health - ARPA-H | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Seaport Therapeutics is 5.7K monthly website visits, down 25% over the last three months. Seaport Therapeutics's team grew 17.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Advanced Research Projects Agency for Health - ARPA-H
Series A10 investors entered at this stage
ARCH Venture Partners
Sofinnova Investments
Third Rock Ventures
PureTech
General Atlantic
Invus
CPP Investments
Goldman Sachs
Foresite Capital
T. Rowe Price
Other known investors1 additional known investor
Monash University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Seaport Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Seaport Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.